Advanced Control Specialty Formulary[™]

The **CVS Caremark[®] Advanced Control Specialty Formulary[™]** is a guide within select therapeutic categories for clients, plan members and health care providers. **Generics should be considered the first line of prescribing**. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase *Italics*, and generic products in lowercase *italics*.

PLAN MEMBER

Your benefit plan provides you with a prescription benefit program administered by CVS Caremark. Ask your doctor to consider prescribing, when medically appropriate, a preferred medicine from this list. Take this list along when you or a covered family member sees a doctor.

Please note:

- Your specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the U.S. Food and Drug Administration (FDA) may not be covered upon release to the market.
- Your prescription benefit plan design may alter coverage of certain products or vary copay¹ amounts based on the condition being treated.
- You may be responsible for the full cost of non-formulary products that are removed from coverage.
- For specific information regarding your prescription benefit coverage and copay¹ information, please visit <u>www.caremark.com</u> or contact a CVS Caremark Customer Care representative.
- CVS Caremark may contact your doctor after receiving your prescription to request consideration of a drug list product or generic equivalent. This may result in your doctor prescribing, when medically appropriate, a different brand-name product or generic equivalent in place of your original prescription.
- In most instances, a brand-name drug for which a generic product becomes available will be designated as a nonpreferred option upon release of the generic product to the market.

ANALGESICS

VISCOSUPPLEMENTS DUROLANE GEL-ONE GELSYN-3 SUPARTZ FX VISCO-3

ANTI-INFECTIVES

ANTIRETROVIRAL AGENTS § ANTIRETROVIRAL COMBINATIONS abacavir-lamivudine lamivudine-zidovudine ATRIPLA BIKTARVY COMPLERA DESCOVY EVOTAZ GENVOYA ODEFSEY PREZCOBIX STRIBILD TRIUMEQ TRUVADA FUSION INHIBITORS FUZEON

INTEGRASE INHIBITORS ISENTRESS TIVICAY

§ NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS efavirenz nevirapine nevirapine ext-rel EDURANT INTELENCE § NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

abacavir tablet didanosine lamivudine stavudine zidovudine EMTRIVA

NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS VIREAD

§ PROTEASE INHIBITORS lopinavir-ritonavir solution KALETRA TABLET NORVIR

PREZISTA

REYATAZ

ANTIVIRALS

§ HEPATITIS B AGENTS entecavir tablet lamivudine BARACLUDE SOLUTION VEMLIDY

§ HEPATITIS C AGENTS ribavirin EPCLUSA (genotypes 1, 2, 3, 4, 5, 6) HARVONI (genotypes 1, 4, 5, 6) VOSEVI ²

ANTINEOPLASTIC AGENTS

§ ALKYLATING AGENTS temozolomide

§ ANTIMETABOLITES capecitabine

HEALTH CARE PROVIDER

Your patient is covered under a prescription benefit plan administered by CVS Caremark. As a way to help manage health care costs, authorize generic substitution whenever possible. If you believe a brand-name product is necessary, consider prescribing a brand name on this list.

Please note:

- Generics should be considered the first line of prescribing.
- The member's prescription benefit plan design may alter coverage of certain products or vary copay¹ amounts based on the condition being treated.
- This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. The member's specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. Products recently approved by the FDA may not be covered upon release to the market.
- The member's prescription benefit plan may have a different copay¹ for specific products on the list.
- Unless specifically indicated, drug list products will include all dosage forms.
- Log in to <u>www.caremark.com</u> to check coverage and copay¹ information for a specific medicine.

HORMONAL ANTINEOPLASTIC AGENTS ANTIANDROGENS ERLEADA XTANDI ZYTIGA

§ LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AGONISTS leuprolide acetate ELIGARD

IMMUNOMODULATORS REVLIMID THALOMID

§ KINASE INHIBITORS imatinib mesylate AFINITOR BOSULIF



CABOMETYX IBRANCE IRESSA KISQALI KISQALI FEMARA CO-PACK NEXAVAR RYDAPT SPRYCEL SUTENT TARCEVA TYKERB VOTRIENT

§ MISCELLANEOUS

bexarotene capsule ODOMZO ZEJULA ZOLINZA

CARDIOVASCULAR

ANTILIPEMICS PCSK9 INHIBITORS REPATHA

PULMONARY ARTERIAL HYPERTENSION

ENDOTHELIN RECEPTOR ANTAGONISTS LETAIRIS

OPSUMIT TRACLEER

§ PHOSPHODIESTERASE INHIBITORS sildenafil

PROSTACYCLIN RECEPTOR AGONISTS UPTRAVI

PROSTAGLANDIN VASODILATORS ORENITRAM CENTRAL NERVOUS SYSTEM

§ HUNTINGTON'S DISEASE AGENTS tetrabenazine AUSTEDO

§ MULTIPLE SCLEROSIS AGENTS glatiramer AUBAGIO BETASERON

COPAXONE GILENYA REBIF TECFIDERA TYSABRI

ENDOCRINE AND METABOLIC

ACROMEGALY SOMATULINE DEPOT SOMAVERT

CALCIUM REGULATORS PARATHYROID HORMONES FORTEO TYMLOS

MISCELLANEOUS PROLIA

CONTRACEPTIVES PROGESTIN INTRAUTERINE DEVICES KYLEENA MIRENA SKYLA

FERTILITY REGULATORS GNRH / LHRH ANTAGONISTS CETROTIDE OVULATION STIMULANTS, GONADOTROPINS GONAL-F OVIDREL

GAUCHER DISEASE CERDELGA CEREZYME

HEREDITARY TYROSINEMIA TYPE 1 AGENTS ORFADIN

HUMAN GROWTH HORMONES HUMATROPE

§ UREA CYCLE DISORDERS sodium phenylbutyrate

MISCELLANEOUS CYSTAGON

HEMATOLOGIC

HEMATOPOIETIC GROWTH FACTORS ARANESP PROCRIT ZARXIO

HEMOPHILIA A AGENTS ADYNOVATE JIVI KOGENATE FS KOVALTRY NOVOEIGHT NUWIQ

HEMOPHILIA B AGENTS REBINYN

HEREDITARY ANGIOEDEMA RUCONEST

IMMUNOLOGIC AGENTS

ALLERGENIC EXTRACTS ORALAIR AUTOIMMUNE AGENTS See Table 1 for Indication Based Coverage Details

ANKYLOSING SPONDYLITIS COSENTYX ENBREL HUMIRA

CROHN'S DISEASE HUMIRA STELARA SUBCUTANEOUS **#**

After failure of HUMIRA

PSORIASIS HUMIRA OTEZLA STELARA SUBCUTANEOUS TALTZ

PSORIATIC ARTHRITIS COSENTYX ENBREL HUMIRA OTEZLA

RHEUMATOID ARTHRITIS ENBREL HUMIRA KEVZARA ORENCIA CLICKJECT ORENCIA SUBCUTANEOUS XELJANZ XELJANZ XR

ULCERATIVE COLITIS HUMIRA SIMPONI #

After failure of HUMIRA

ALL OTHER CONDITIONS ENBREL HUMIRA

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs) RASUVO

IMMUNOSUPPRESSANTS

§ ANTIMETABOLITES mycophenolate mofetil mycophenolate sodium

§ CALCINEURIN INHIBITORS cyclosporine cyclosporine, modified tacrolimus

§ RAPAMYCIN DERIVATIVES sirolimus tablet RAPAMUNE SOLUTION

RESPIRATORY

§ CYSTIC FIBROSIS tobramycin inhalation solution BETHKIS

PULMONARY ENZYME DEFICIENCY AGENTS ARALAST NP

GLASSIA PROLASTIN-C

PULMONARY FIBROSIS AGENTS ESBRIET OFEV

SEVERE ASTHMA AGENTS NUCALA

TOPICAL

DERMATOLOGY ATOPIC DERMATITIS DUPIXENT

MOUTH / THROAT / DENTAL AGENTS PROTECTANTS MUGARD

A abacavir tablet abacavir-lamivudine ADYNOVATE AFINITOR ARALAST NP ARANESP ATRIPLA AUBAGIO AUSTEDO

В

BARACLUDE SOLUTION BETASERON BETHKIS C CABOMETYX capecitabine CERDELGA CEREZYME CETROTIDE COMPLERA COPAXONE COSENTYX cyclosporine

bexarotene capsule

BIKTARVY

BOSULIF

QUICK REFERENCE DRUG LIST

cyclosporine, modified CYSTAGON DESCOVY didanosine DUPIXENT DUROLANE E EDURANT efavirenz ELIGARD EMTRIVA ENBREL

EPCLUSA ERLEADA ESBRIET EVOTAZ F FORTEO FUZEON G GEL-ONE GELSYN-3 GENVOYA GILENYA

entecavir tablet

GLASSIA glatiramer GONAL-F

H Harvoni Humatrope Humira

Т

IBRANCE imatinib mesylate INTELENCE IRESSA ISENTRESS



J

JIVI

Κ

KALETRA TABLET KEVZARA KISQALI KISQALI FEMARA CO-PACK KOGENATE FS KOVALTRY KYLEENA

L

lamivudine lamivudine-zidovudine LETAIRIS leuprolide acetate lopinavir-ritonavir solution

Μ

MIRENA MUGARD mycophenolate mofetil mycophenolate sodium

Ν

nevirapine nevirapine ext-rel NEXAVAR NORVIR NOVOEIGHT NUCALA NUWIQ

0

ODEFSEY ODOMZO OFEV OPSUMIT ORALAIR ORENCIA CLICKJECT ORENCIA SUBCUTANEOUS ORENITRAM ORFADIN OTEZLA OVIDREL

PREZCOBIX

PREZISTA PROCRIT PROLASTIN-C PROLIA

R

RAPAMUNE SOLUTION RASUVO REBIF REBINYN REPATHA REVLIMID REYATAZ ribavirin RUCONEST RYDAPT S sildenafil SIMPONI sirolimus tablet SKYLA sodium phenylbutyrate

stavudine STELARA SUBCUTANEOUS STRIBILD SUPARTZ FX SUTENT

т tacrolimus TALTZ TARCEVA **TECFIDERA** temozolomide tetrabenazine THALOMID TIVICAY tobramycin inhalation solution TRACLEER TRIUMEQ TRUVADA **TYKERB TYMLOS TYSABRI**

U

UPTRAVI

v

VEMLIDY VIREAD VISCO-3 VOSEVI² VOTRIENT

Χ

XELJANZ XELJANZ XR XTANDI

Z

ZARXIO ZEJULA *zidovudine* ZOLINZA ZYTIGA

PREFERRED	OPTIONS FOR	FXCLUDED	SPECIAL TY N	IEDICATIONS 3

SOMATULINE DEPOT

SOMAVERT

SPRYCEL

DRUG NAME(S)	PREFERRED OPTION(S)*	DRUG NAME(S)	PREFERRED OPTION(S)*	
ADCIRCA	sildenafil	NUTROPIN AQ	HUMATROPE	
ALPROLIX	Consult doctor	OMNITROPE	HUMATROPE	
BERINERT	RUCONEST	ORTHOVISC	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3	
BRAVELLE	GONAL-F	OTREXUP	RASUVO	
BUPHENYL	sodium phenylbutyrate	PEGASYS	Consult doctor	
DAKLINZA	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6),	PRALUENT	REPATHA	
	HARVONI (genotypes 1, 4, 5, 6)	PROCYSBI	CYSTAGON	
ELELYSO		PROGRAF	tacrolimus	
ELOCTATE	ADYNOVATE, JIVI, KOGENATE FS, KOVALTRY, NOVOEIGHT, NUWIQ	RAVICTI	sodium phenylbutyrate	
EUFLEXXA	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3	REVATIO	sildenafil	
EXTAVIA	glatiramer, AUBAGIO, BETASERON, COPAXONE, GILENYA, REBIF, TECFIDERA, TYSABRI	SAIZEN	HUMATROPE	
		SANDOSTATIN LAR	SOMATULINE DEPOT, SOMAVERT	
FASENRA	NUCALA	SYNVISC, SYNVISC-ONE	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3	
FOLLISTIM AQ	GONAL-F	TASIGNA	imatinib mesylate, BOSULIF, SPRYCEL	
GENOTROPIN	HUMATROPE	TECHNIVIE	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6),	
GLEEVEC	imatinib mesylate, BOSULIF, SPRYCEL		HARVONI (genotypes 1, 4, 5, 6)	
HELIXATE FS	ADYNOVATE, JIVI, KOGENATE FS, KOVALTRY,	TOBI	tobramycin inhalation solution, BETHKIS	
	NOVOEIGHT, NUWIQ	TOBI PODHALER	tobramycin inhalation solution, BETHKIS	
HYALGAN	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3	VIEKIRA PAK	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6)	
LILETTA	KYLEENA, MIRENA, SKYLA			
LUPRON DEPOT (For Prostate Cancer Only)	ELIGARD	VIEKIRA XR	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6)	
MAVYRET	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6),	XENAZINE	tetrabenazine, AUSTEDO	
	HARVONI (genotypes 1, 4, 5, 6), VOSEVI ²		ARALAST NP, GLASSIA, PROLASTIN-C	
MONOVISC	DUROLANE, GEL-ONE, GELSYN-3, SUPARTZ FX, VISCO-3	ZEPATIER	EPCLUSA (genotypes 1, 2, 3, 4, 5, 6),	
NEUPOGEN	ZARXIO		HARVONI (genotypes 1, 4, 5, 6)	
NORDITROPIN	HUMATROPE			



TABLE 1 - PREFERRED OPTIONS FOR INDICATION BASED AUTOIMMUNE EXCLUDED MEDICATIONS

CONDITION	EXCLUDED DRUG NAME(S)	PREFERRED OPTION(S)
ANKYLOSING SPONDYLITIS	CIMZIA SIMPONI	COSENTYX ENBREL HUMIRA
CROHN'S DISEASE	CIMZIA ENTYVIO	HUMIRA STELARA SUBCUTANEOUS #
PSORIASIS	CIMZIA COSENTYX ENBREL	HUMIRA OTEZLA STELARA SUBCUTANEOUS TALTZ
PSORIATIC ARTHRITIS	CIMZIA ORENCIA CLICKJECT ORENCIA INTRAVENOUS ORENCIA SUBCUTANEOUS SIMPONI STELARA SUBCUTANEOUS TALTZ XELJANZ XELJANZ XR	COSENTYX ENBREL HUMIRA OTEZLA
RHEUMATOID ARTHRITIS	ACTEMRA CIMZIA KINERET ORENCIA INTRAVENOUS SIMPONI	ENBREL HUMIRA KEVZARA ORENCIA CLICKJECT ORENCIA SUBCUTANEOUS XELJANZ XELJANZ XR
ULCERATIVE COLITIS	ENTYVIO XELJANZ	HUMIRA SIMPONI #
ALL OTHER CONDITIONS	ACTEMRA KINERET ORENCIA CLICKJECT ORENCIA INTRAVENOUS ORENCIA SUBCUTANEOUS	ENBREL HUMIRA

After failure of HUMIRA



You may be responsible for the full cost of certain non-formulary products that are removed from coverage. Please check with your plan sponsor for more information.

FOR YOUR INFORMATION: Generics should be considered the first line of prescribing. This drug list represents a summary of prescription coverage. It is not all-inclusive and does not guarantee coverage. New-to-market products and new variations of products already in the marketplace will not be added to the formulary immediately. Each product will be evaluated for clinical appropriateness and cost-effectiveness. Recommended additions to the formulary will be presented to the CVS Caremark National Pharmacy and Therapeutics Committee (or other appropriate reviewing body) for review and approval. In most instances, a brand-name drug for which a generic product becomes available will be designated as a non-preferred option upon release of the generic product to the market. Specific prescription benefit plan design may not cover certain products or categories, regardless of their appearance in this document. The member's prescription benefit plan may have a different copay¹ for specific products on the list. Unless specifically indicated, drug list products will include all dosage forms. This list represents brand products in CAPS, branded generically in certain strengths or dosage forms. Dosage forms on this list will be consistent with the category and use where listed. Log in to www.caremark.com to check coverage and copay¹ information for a specific medicine.

- * The preferred options in this list are a broad representation within therapeutic categories of available treatment options and do not necessarily represent clinical equivalency.
- § Generics are available in this class and should be considered the first line of prescribing.
- ¹ Copayment, copay or coinsurance means the amount a member is required to pay for a prescription in accordance with a Plan, which may be a deductible, a percentage of the prescription price, a fixed amount or other charge, with the balance, if any, paid by a Plan.
- ² For use in patients previously treated with an HCV regimen containing an NS5A inhibitor (for genotypes 1-6) or sofosbuvir without an NS5A inhibitor (for genotypes 1 a or 3).
- ³ An exception process is in place for specific clinical or regulatory circumstances that may require coverage of an excluded medication.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

CVS Caremark may receive rebates, discounts and service fees from pharmaceutical manufacturers for certain listed products. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber. The document is subject to state-specific regulations and rules, including, but not limited to, those regarding generic substitution, controlled substance schedules, preference for brands and mandatory generics whenever applicable.

The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2018 CVS Caremark. All rights reserved. 106-31697C 010119

www.caremark.com

